Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence and patient experience study of erlotinib in NSCLC
NL-OMON26332Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam UMC. Primary endpoints: Adherence rate, Plasma concentration of erlotinib and 1 more. Started Jul 2009; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON26332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26332.